Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.73, $0.11 worse than the analyst estimate of $3.84. Revenue for the quarter came in at $813.7 million versus the consensus estimate of $852.75 million.

GUIDANCE:

Jazz Pharmaceuticals raises FY2022 revenue to $3.5-3.7 billion, versus the consensus of $3.58 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.